CagriSema May Not Be Enough to Restore Novo Nordisk’s Obesity Lead
Novo Nordisk did not lose momentum because CagriSema is a weak drug. That is too simple. The sharper problem is that CagriSema is being asked to solve a structural challenge: Lilly has already taken the efficacy lead with tirzepatide, is pushing the ceiling higher with retatrutide, and is building a broader obesity portfolio while Novo […]
CagriSema May Not Be Enough to Restore Novo Nordisk’s Obesity Lead Read More »
